These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 34522165)
1. Hypothesis: Immunotherapy by Selective Convalescent Blood Engineering to Stifle Diseases like COVID-19. Mukherjee AP Int J Med Sci; 2021; 18(15):3389-3394. PubMed ID: 34522165 [TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma - Is it useful for treating SARS Co-V2 infection? Ranganathan S; Iyer RN Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232 [TBL] [Abstract][Full Text] [Related]
3. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment. Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273 [TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma may be a possible treatment for COVID-19: A systematic review. Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
6. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293 [TBL] [Abstract][Full Text] [Related]
7. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042 [TBL] [Abstract][Full Text] [Related]
8. Passive immunization and its rebirth in the era of the COVID-19 pandemic. Pavia CS; Wormser GP Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975 [TBL] [Abstract][Full Text] [Related]
9. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N Front Immunol; 2021; 12():613502. PubMed ID: 33968017 [TBL] [Abstract][Full Text] [Related]
10. Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies. Hassan M; Zalkifal M; Wahab A; Afzal S; Rafique S; Shahid M; Khan MA; Ahmed N; Idrees M; Shahid AA Crit Rev Eukaryot Gene Expr; 2021; 31(3):21-34. PubMed ID: 34369712 [TBL] [Abstract][Full Text] [Related]
11. Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. Kurtović T; Ravlić S; Štimac A; Mateljak Lukačević S; Hećimović A; Kazazić S; Halassy B Front Immunol; 2022; 13():889736. PubMed ID: 35655779 [TBL] [Abstract][Full Text] [Related]
12. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
13. Current Scenario and Future Prospect in the Management of COVID-19. Borah P; Deb PK; Deka S; Venugopala KN; Singh V; Mailavaram RP; Kalia K; Tekade RK Curr Med Chem; 2021; 28(2):284-307. PubMed ID: 32900341 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial. Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167 [TBL] [Abstract][Full Text] [Related]
16. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM Front Immunol; 2020; 11():569760. PubMed ID: 33362758 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors. Bansal N; Raturi M; Bansal Y Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 convalescent plasma: current status, lessons from the past and future perspectives. Hervig TA; Flesland Ø; Nissen-Meyer LSH Transfus Apher Sci; 2022 Aug; 61(4):103487. PubMed ID: 35778352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]